Cytokinetics to Present Key Aficamten Data at ESC Congress 2026
Event summary
- Cytokinetics will present primary results from the ACACIA-HCM trial for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM) at ESC Congress 2026.
- Hot Line presentation scheduled for August 28, 2026, with additional Late-Breaking Science presentations on August 29, 2026.
- Company to host an in-person and virtual investor event on August 28, 2026, to discuss the results.
- Aficamten is already approved for obstructive hypertrophic cardiomyopathy (oHCM) in the U.S., China, EU, and UK.
The big picture
Cytokinetics is positioning aficamten as a potential cornerstone therapy for both obstructive and non-obstructive hypertrophic cardiomyopathy, a strategic move that could significantly expand its addressable market. The ESC Congress presentations will be critical in validating the drug's efficacy and safety profile in a broader patient population, potentially accelerating regulatory approvals and commercial adoption. The company's focus on cardiac muscle dysfunction aligns with growing demand for targeted therapies in cardiovascular disease.
What we're watching
- Regulatory Pathway
- Whether the ACACIA-HCM results will support a regulatory filing for aficamten in non-obstructive hypertrophic cardiomyopathy.
- Market Expansion
- The potential size of the non-obstructive hypertrophic cardiomyopathy treatment population and aficamten's market penetration.
- Clinical Efficacy
- How the detailed ACACIA-HCM data compares to existing treatments and impacts physician prescribing behavior.